FIELD: medicine.
SUBSTANCE: patient is introduced with erythropoietin (EPO). Thus the first dose of EPO is introduced within time space 8 hours and 24 hours following ischemia event. Subsequent second dose of EPO is introduced within 8 to 24 hours following the first dose. Additionally the third dose of EPO is introduced within 20 to 60 hours following ischemia event. EPO doses are chosen from the range 2500 to 5000 ME/kg.
EFFECT: allows for stimulation of CNS functional restoration, inhibition of apoptosis and CNS inflammation associated with delayed initiation of treatment.
26 cl, 1 tbl, 1 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TREATMENT OF NEUROLOGICAL DYSFUNCTION BY USING FRUCTOPYRANOSE AND ERYTHROPOIETIN SULFAMATES | 2002 |
|
RU2317086C2 |
| METHOD FOR CORRECTING MICROCIRCULATION DISORDERS IN KIDNEY WITH PEPTIDE THAT MIMICS ALPHA-HELIX B OF ERYTHROPOIETIN IN ISCHEMIA-REPERFUSION INJURY | 2021 |
|
RU2751413C1 |
| PHARMACEUTICAL COMPOSITIONS OF ERYTHROPOIETIN | 2000 |
|
RU2225221C2 |
| VERSIONS OF ERYTHROPOETINE | 2006 |
|
RU2430162C2 |
| METHOD FOR TREATING CEREBRAL ISCHEMIAS AND APPLICATION OF ERYTHROPOIETIN OR ITS DERIVATIVES IN TREATING CEREBRAL ISCHEMIAS | 1999 |
|
RU2242991C2 |
| TREATING A HEART ATTACK AND ISCHEMIC INJURY WITH HALOGEN COMPOUNDS | 2015 |
|
RU2728790C2 |
| METHOD FOR PREVENTING MICROCIRCULATION DISORDERS IN KIDNEYS WITH ASIALISED ERYTHROPOIETIN IN EXPERIMENT | 2018 |
|
RU2696864C1 |
| COMPOSITIONS AND METHODS FOR TREATMENT DURING NON-ACUTE PERIODS FOLLOWING NEUROLOGICAL CNS DAMAGE | 2013 |
|
RU2646507C2 |
| COMPOSITIONS FOR TREATING CEREBRAL LESIONS | 2016 |
|
RU2710543C2 |
| METHOD OF TREATING CEREBRAL ISCHEMIA IN EXPERIMENT | 2012 |
|
RU2495688C1 |
